Autolus Therapeutics (AUTL) Return on Equity (2018 - 2025)

Autolus Therapeutics (AUTL) has 8 years of Return on Equity data on file, last reported at 0.01% in Q4 2025.

• For the quarter ending Q4 2025, Return on Equity fell 1.0% year-over-year to 0.01%; the trailing twelve-month figure through Dec 2025 stood at 0.01% (down 1.0% YoY), and the FY2025 full-year result was 0.01%, changed 0.0% from the prior year.
• Return on Equity for Q4 2025 stood at 0.01%, down from 0.01% in the prior quarter.
• Across five years, Return on Equity topped out at 0.0% in Q2 2024 and bottomed at 1.85% in Q2 2022.
• The 5-year median for Return on Equity is 0.01% (2022), against an average of 0.34%.
• The widest annual swing landed in 2022, when Return on Equity slumped 184 bps; it then soared 184 bps in 2023.
• A 5-year view of Return on Equity shows it stood at 1.61% in 2021, then jumped by 100 bps to 0.01% in 2022, then slumped by 120 bps to 0.01% in 2023, then soared by 66 bps to 0.0% in 2024, then slumped by 166 bps to 0.01% in 2025.
• The last three Return on Equity figures came in at 0.01% (Q4 2025), 0.01% (Q3 2025), and 0.01% (Q2 2025), per Business Quant data.

Peer Comparison